Mitral Valve Disease Market Trends : is Expected to Attain USD 5.7 billion by 2031 , Claims AMR

The mitral valve disease market size was valued at $2.5 billion in 2021, and is estimated to reach $5.7 billion by 2031, growing at a CAGR of 8.8% from 2022 to 2031.

Drivers-

The rising incidence of mitral valve disorders and the advancement of cutting-edge technologies for treating such conditions stand as crucial trends propelling the growth of the mitral valve disease market. Moreover, the increasing need for less invasive surgical interventions to address dysfunctional mitral valves is a key driver influencing the market’s expansion. This demand stems from the recognition that conventional open-heart surgery for mitral valve replacement is an invasive procedure entailing lengthy recovery periods and significant potential complications.

Request Sample Copy of Report- 

https://www.alliedmarketresearch.com/request-sample/75123

In 2021, North America dominated the mitral valve disease market in terms of revenue, primarily due to a concerning rise in the occurrence of valvular heart diseases, including mitral valve disease, within the region. This trend can be linked to lifestyle factors such as sedentary living, poor dietary habits, and an aging population. Moreover, the market is being fueled by a growing demand for products related to the treatment of mitral valve disease and an increasing preference for less invasive procedures.

Conversely, the Asia-Pacific region is projected to experience the most substantial growth throughout the forecast period in the mitral valve disease market. This can be attributed to a significant increase in the demand for minimally invasive mitral valve procedures, aimed at meeting the unmet healthcare requirements of a sizable population. Furthermore, the advancement of healthcare infrastructure, the implementation of healthcare reforms, and an upsurge in healthcare spending in emerging economies are expected to play a vital role in fostering the expansion of the mitral valve disease market in the Asia-Pacific region.

𝐏𝐫𝐨𝐜𝐮𝐫𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 (374+ 𝐏𝐚𝐠𝐞𝐬 𝐏𝐃𝐅 𝐰𝐢𝐭𝐡 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐂𝐡𝐚𝐫𝐭𝐬, 𝐓𝐚𝐛𝐥𝐞𝐬, 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬: https://www.alliedmarketresearch.com/mitral-valve-disease-market/purchase-options

Recent Approvals in Mitral Valve Disease Market

• In January 2020, Abbott received the CE Mark approval of Abbott’s Tendyne Transcatheter Mitral Valve Implantation (TMVI) system used in the treatment of mitral regurgitation (MR) in patients who require a heart valve replacement and is now approved for use in Europe.
• In September 2021, Abbott received the U.S. Food and Drug Administration (FDA) approval for Epic Plus and Epic Plus Supra Stented Tissue Valves. These new devices are based on Abbott’s Epic surgical valve platform, which improve therapy options for people with aortic or mitral valve disease.

Divestment in Mitral Valve Disease Market 

• In June 2021, Corcym announced the launch of its operations globally, which is formed from the acquisition of the LivaNova Plc. heart valve business by Gyrus Capital. The new, independent, medical device company will be dedicated towards providing patients and heart surgeons with the best solutions to fight structural heart disease.

Investment in the Mitral Valve Disease Market 

• In March 2019, Edwards Lifesciences Corporation has announced two strategic transactions involving companies with structural heart disease technologies. The transaction involves a $35 million investment in an exclusive right to acquire Corvia Medical, Inc. and the acquisition of certain assets of Mitralign, Inc, a company that specializes in developing devices for the treatment of mitral valve regurgitation.

New Product Development in Mitral Valve Disease Market

• In November 2021, Medtronic plc. presented early data for Intrepid transcatheter mitral valve replacement (TMVR) system in patients with severe, symptomatic mitral valve regurgitation (MR) utilizing the transfemoral access route. The data from first 5 patients enrolled in an Early Feasibility Study of the Intrepid Transfemoral System showed 100% survival and no stroke and none or trace MR in all implanted patients at 30 days.

𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐘𝐨𝐮𝐫 𝐄𝐯𝐞𝐫𝐲 𝐃𝐨𝐮𝐛𝐭 𝐇𝐞𝐫𝐞: https://www.alliedmarketresearch.com/purchase-enquiry/74863

Mitral Valve Disease Market Segmentation

Mitral Valve Disease Market Key Players

1. Medtronic plc
2. Labcor Laboratorios Ltda
3. Pfizer Inc.
4. Novartis AG
5. ShockWave Medical, Inc.
6. Braile Biomedica
7. Corcym UK Limited
8. Artivion, Inc.
9. Edwards Lifesciences Corporation
10. Affluent Medical
11. Bayer AG
12. Zydus Lifesciences Limited
13. Teva Pharmaceutical Industries Ltd.
14. Abbott Laboratories
15. Valcare Medical

Key findings of the study
• On the basis of treatment type, the mitral valve repair segment was highest contributor to the market in 2021; however, the mitral valve replacement segment is anticipated to grow at the fastest rate during the forecast period.
• Depending on indication, the mitral valve regurgitation segment dominated the mitral valve disease industry in 2021; however, the mitral valve stenosis segment is anticipated to grow at the highest CAGR in the coming future.
• By end user, the hospitals segment led the mitral valve disease industry in 2021 and is anticipated to grow at the highest CAGR.
• Region wise, North America generated the largest revenue in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

𝐎𝐭𝐡𝐞𝐫 𝐓𝐨𝐩 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐢𝐧 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐃𝐨𝐦𝐚𝐢𝐧 –

Flow Diverters Market https://www.alliedmarketresearch.com/flow-diverters-market-A17519

Speech Therapy Market https://www.alliedmarketresearch.com/speech-therapy-market-A31451

Specialty Medical Chairs Market https://www.alliedmarketresearch.com/specialty-medical-chairs-market-A11457